Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression by Zhou, H. et al.
Semaphorin 4D cooperates with VEGF to promote angiogenesis
and tumor progression
Hua Zhou,
Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 650
West Baltimore Street, 7-North, Baltimore, MD 21201, USA
Nada O. Binmadi,
Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 650
West Baltimore Street, 7-North, Baltimore, MD 21201, USA. Department of Oral Basic and
Clinical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Ying-Hua Yang,
Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 650
West Baltimore Street, 7-North, Baltimore, MD 21201, USA
Patrizia Proia, and
Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 650
West Baltimore Street, 7-North, Baltimore, MD 21201, USA. Department of Sports Science
(DISMOT), University of Palermo, Via M. Toselli, 87/B, 90143 Palermo, Italy
John R. Basile
Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 650
West Baltimore Street, 7-North, Baltimore, MD 21201, USA. Greenebaum Cancer Center, 22 S.
Greene Street, Baltimore, MD 21201, USA
John R. Basile: jbasile@umaryland.edu
Abstract
The semaphorins and plexins comprise a family of cysteine-rich proteins implicated in control of
nerve growth and development and regulation of the immune response. Our group and others have
found that Semaphorin 4D (SEMA4D) and its receptor, Plexin-B1, play an important role in
tumor-induced angiogenesis, with some neoplasms producing SEMA4D in a manner analogous to
vascular endothelial growth factor (VEGF) in order to attract Plexin-B1-expressing endothelial
cells into the tumor for the purpose of promoting growth and vascularity. While anti-VEGF
strategies have been the focus of most angiogenesis inhibition research, such treatment can lead to
upregulation of pro-angiogenic factors that can compensate for the loss of VEGF, eventually
leading to failure of therapy. Here, we demonstrate that SEMA4D cooperates with VEGF to
promote angiogenesis in malignancies and can perform the same function in a setting of VEGF
blockade. We also show the potential value of inhibiting SEMA4D/Plexin-B1 signaling as a
complementary mechanism to anti-VEGF treatment, particularly in VEGF inhibitor–resistant
tumors, suggesting that this may represent a novel treatment for some cancers.
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Introduction
Vascular endothelial growth factor (VEGF) plays a unique role in physiological and
pathological angiogenesis. VEGF promotes endothelial cell proliferation and migration,
increases vascular permeability and inhibits apoptosis of endothelial cells lining newly
formed vessels. There are numerous splice isoforms of VEGF that bind with varying degrees
of affinity to VEGF receptors (VEGFR) on the surface of endothelial cells. Most of the
angiogenic effects attributed to VEGF are a result of activation of VEGFR-2, which signals
through the phosphatidyl-inositol 3 kinase (PI3K)/Akt pathway [1]. VEGFR-1, on the other
hand, was initially thought to act as a decoy receptor that sequestered VEGF, rendering it
less available to VEGFR-2 [2]. More recently, studies have suggested that VEGFR-1 has a
functional role in angiogenesis as well [3].
VEGF transcription is stimulated by hypoxia-inducible factor (HIF)-1 binding to hypoxia
response elements within the VEGF promoter [4]. It is therefore an important protein
produced by rapidly expanding neoplasms that begin to outgrow their blood supply or are
exposed to chemotherapy-or radiotherapy-induced hypoxia in order to attract blood vessels
into the tumor for the purposes of promoting survival and metastasis. Several promising
therapeutic strategies are in development that specifically exploits the dependence of tumors
on VEGF production, and it has become a tempting target for neutralizing antibodies in the
treatment of advanced neoplasms. However, it is known that other angiogenic factors such
as SDF-1, FGF-1 and -2, PlGF, and MMP9 can be elevated in tumors following anti-VEGF
therapy, allowing them to overcome angio-genesis inhibition approaches that target only one
factor [5]. Therefore, combination therapy with multiple anti-angiogenic agents might be
recommended for more effective treatment.
The semaphorins were originally identified as axon guidance factors and regulators of
proliferation and activation of lymphocytes [6, 7]. Currently, more than 20 semaphorins
have been identified, which are grouped into eight classes: classes 1 and 2 are invertebrate
semaphorins, classes 3–7 are found in vertebrates, and an eighth class, class V, has been
identified in some non-neurotropic DNA viruses. Plexins, which are the functional receptors
for the semaphorins, share homology in their extracellular segment with the scatter factor
receptors c-Met and RON. In humans, at least nine plexins have been identified and grouped
into four families, A through D, most of which have been shown to mediate neuronal cell
adhesion and contact, nerve fasciculation, and axon guidance [8]. Some semaphorins, such
as those in class 3, require co-receptors, the neuropilins (NPs), to bind and initiate
intracellular signaling through the plexins [9]. In the case of Semaphorin 4D (SEMA4D),
signaling is mediated directly through binding to its single-pass transmembrane receptor,
Plexin-B1.
In addition to their better-defined functions, a variety of semaphorins and plexins are known
to play a critical role in blood vessel guidance and endothelial precursor cell homing during
physiological and pathological blood vessel development, with the class 3 semaphorins
being the most highly studied in this regard [10]. Class 3 semaphorins have been shown to
act through their receptors, the NPs and the A-family plexins, to initiate signaling events in a
variety of tissues that influence vascular morphogenesis and endothelial cell motility [11].
Our group and others have shown that SEMA4D is shed from the surface of tumor cells and
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acts through Plexin-B1 on endothelial cells to promote angiogenesis and tumor growth and
survival [12–14]. Here, we demonstrate that SEMA4D is increased in the setting of VEGF
inhibition in head and neck squamous cell carcinoma (HNSCC). Using in vivo and in vitro
angiogenesis assays, RNA interference and blocking antibodies, we examine the
contributions of the SEMA4D/Plexin-B1 system to tumor-induced angiogenesis when
compared to VEGF and demonstrate that targeting these proteins might represent a
complementary or parallel mode of treatment for anti-angiogenic therapy of HNSCC and
other solid tumors exhibiting insensitivity to anti-VEGF therapy.
Materials and methods
Cell culture
Human umbilical vein endothelial cells (HUVEC, ATCC, Manassas, VA) were cultured in
Endothelial Cell Medium-2 (EGM-2, Lonza). 293T cells (ATCC) and the HNSCC cell lines
HN12 [15], 13, and 30 (gifts of Dr. J. Silvio Gutkind) were cultured in DMEM (Sigma, St.
Louis, MO). Media for the HN lines were supplemented with 10 % fetal bovine serum and
100 units/ml penicillin/streptomycin/amphotericin B (Sigma). CT26 cells (ATCC) were
cultured in RPMI-1640 (Mediatech, Manassas, VA) supplemented with 10 % fetal bovine
serum and 100 units/ml penicillin/streptomycin/amphotericin B (Sigma).
Production of soluble SEMA4D
Soluble SEMA4D (sSEMA4D) was produced and purified as described previously [12].
Briefly, the extracellular portion of SEMA4D was subjected to PCR and the resulting
product cloned into the plasmid pSecTag2B (Invitrogen, Carlsbad, CA). This construct was
transfected into 293T cells growing in serum-free media. Media containing sSEMA4D was
collected 65 h post-transfection and purified with TALON metal affinity resin (Clontech
Laboratories, Palo Alto, CA) according to manufacturer’s instructions. Concentration and
purity of the TALON eluates was determined by SDS PAGE analysis followed by silver
staining (Amersham Life Science, Piscataway, NJ) and the Bio-Rad protein assay (Bio-Rad,
Hercules, CA). In all cases, media collected from cells transfected with the empty
pSecTag2B vector were used as control.
Immunoblot analysis
Cells were infected with the shRNA lentiviral constructs or treated as indicated and lysed in
lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1 % NP 40) supplemented with protease
inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 1 μl/ml aprotinin and leupeptin, Sigma)
and phosphatase inhibitors (2 mM NaF and 0.5 mM sodium orthovanadate, Sigma) for 15
min at 4 °C. After centrifugation, protein concentrations were measured using the Bio-Rad
protein assay (Bio-Rad). 100 μg of protein from each sample was subjected to SDS–
polyacrylamide gel electrophoresis and transferred onto a PVDF membrane (Immobilon P,
Millipore Corp., Billerica, MA). The membranes were stained with Ponceau red (Sigma),
cut into sections containing the proteins of interest, and then simultaneously probed for
SEMA4D (BD Transduction Labs, BD Biosciences, Palo Alto, CA, Cat#: 610670), Plexin-
B1 (Santa Cruz A8, Santa Cruz, CA), VEGFR-2 (Santa Cruz Biotech), VEGF (Santa Cruz
Biotech), and the loading control, GAPDH (Sigma). Proteins were detected using the ECL
chemiluminescence system (Pierce, Rockford, IL).
Short hairpin (sh) RNA and lentiviral infections
The shRNA sequences for SEMA4D, VEGF, Plexin-B1, and VEGFR-2 were obtained from
Cold Spring Harbor Laboratory’s RNAi library (RNAi Central, http://cancan.cshl.edu/
RNAi_central/RNAi.cgi?type=shRNA) [16, 17]. The sequence used as PCR templates for
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SEMA4D has been previously reported [18]. The sequence for Plexin-B1 shRNA was 5′-
TGC TGT TGA CAG TGA GCG CGC CCA GTA TGT GGC CAA GAA CTA GTG AAG
CCA CAG ATG TAG TTC TTG GCC ACA TAC TGG GCA TGC CTA CTG CCT CGG
A-3′. The sequence used for VEGF was 5′-TGC TGT TGA CAG TGA GCG CGC TTC
CTA CAG CAC AAC AAA TTA GTG AAG CCA CAG ATG TAA TTT GTT GTG CTG
TAG GAA GCT TGC CTA CTG CCT CGG A-3′. The sequence used for VEGFR-2 was
5′-TGC TGT TGA CAG TGA GCG AGC TTG GCC CGG GAT ATT TAT ATA GTG
AAG CCA CAG ATG TAT ATA AAT ATC CCG GGC CAA GCC TGC CTA CTG CCT
CGG A-3′. Oligos were synthesized (Invitrogen) and cloned into pWPI GW, a Gateway-
compatible CSCG-based lentiviral destination vector, as previously described [18–20]. Viral
stocks were prepared and infections performed as previously reported [18, 21, 22]. Control
infections were performed with viruses manufactured with empty expression vectors.
RNA isolation and PCR analysis
RNA was extracted from HN12, 13, and 30 whole cell lysates, control-infected or infected
with VEGF shRNA-expressing lentivirus, and converted into cDNA using the AMV
reverse-transcriptional system (Promega, Madison, WI) in the presence of random hexamers
(Invitrogen). The cDNA was used for quantitative real-time PCR with specific gene primers
as follows: SEMA4D (BC054500) forward: 5′-GTCTTCAAAGAAGGGCAACAGG-3′,
reverse: 5′-GA GCATTTCAGTTCCGCTGTG-3′; and 18S forward: 5′-TT
GACGGAAGGGCACCACCAG-3′, reverse: 5′-GCACCA CCACCCACGGAATCG-3′.
An MYIQ real-time PCR detection system and SYBR green PCR mix (Bio-Rad) were used
to carry out real-time PCR. The relative abundance of SEMA4D transcript was quantified
using the comparative Ct method with 18S as an internal control. All data were analyzed
from three independent experiments and statistical significance validated by Student’s t test.
In vitro migration assay
Serum-free media conditioned by the indicated cells or containing 400 ng/ml sSEMA4D
and/or 100 ng/ml VEGF, concentrations of protein chosen based upon prior published
migration assays [12, 23–26], were placed in the bottom well of a Boyden chamber while
serum-free media containing migrating HUVEC cells previously infected with lentiviruses
encoding the appropriate shRNA were added to the top chamber. The two chambers were
separated by a polyvinylpyrrolidone membrane (8 μ pore size, Osmonics; GE Water
Technologies, Trevose, PA) and the migration assay performed as described [12]. Cell
migration was expressed as membrane-staining intensity relative to the negative control
wells containing 0.1 % BSA. 10 % FBS was used as the positive control. Each experiment
was performed three times and average and standard deviation calculated.
In vivo tubulogenesis assay
HUVEC, untreated or previously infected with lentiviruses encoding the appropriate
shRNA, where indicated, were grown in 35-mm plates coated with 150 μl of Cultrex
basement membrane extract (Trevigen, Gaithersburg, MD) and incubated overnight in
media containing 0.1 % BSA (negative control), 10 % FBS (positive control), 400 ng/ml
sSEMA4D, 100 ng/ml VEGF, or both sSEMA4D and VEGF, based upon concentrations
used in the migration assays, or in media conditioned by control-infected HN12 cells or cells
infected with lentiviruses encoding the indicated shRNA constructs. Cells were then fixed in
0.5 % glutaraldehyde and photographed. Quantification of results was determined using NIH
Image, measuring and summing the length of all tubular structures observed in 10 random
fields for three independent experiments.
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Directed in vivo angiogenesis assay (DIVAA)
A DIVAA assay (Trevigen) was performed as previously described [27] with modifications.
Briefly, angioreactors were filled with 18 μl of Cultrex reconstituted basement membrane
substrate (Trevigen) containing PBS (negative control), basic fibroblast growth factor (FGF,
positive control), 250 ng of sSEMA4D or 100 ng VEGF, or both, and implanted
subcutaneously into the flanks of immuno-compromised nude mice. Starting at day 1 after
surgery, the mice received i.p. injections of 100 μg of anti-VEGF antibody (R & D Systems
Minneapolis, MN), 100 μg of anti-SEMA4D antibody (VX15, which reacts with both
human and mouse SEMA4D Vaccinex, Rochester, NY), or both anti-SEMA4D and anti-
VEGF antibodies, followed by further injections on days 2, 4, 6, and 8. As negative controls,
the mice were treated with matching isotypes IgG4 and IgG2a. Control antibodies were
added to the treatment groups to match the total amount of protein delivered in the
combination group. The mice were killed on day 9 and the angioreactors removed,
photographed, and processed with FITC-labeled Griffonia lectin (FITC-lectin), an
endothelial cell selective reagent [28, 29], to quantify invasion of endothelial cells into the
angioreactors. Fluorescence was determined in a plate reader as mean relative fluorescence
units for four reactors.
Tumor cell injections and animal studies
2 × 106 HN12 cells, controls or infected ex vivo with lentiviruses coding for SEMA4D
shRNA or VEGF shRNA, or 8 × 104 CT26 cells were resuspended in 100 μl of serum-free
DMEM with an equal volume of liquid Cultrex basement membrane extract (Trevigen) and
injected subcutaneously into immunocompromised nude mice. CT26 and some HN12 tumor
cells were grown in mice receiving i.p. injections of 100 μg of anti-VEGF antibody (R & D
Systems) or 100 μg of anti-SEMA4D antibody (Vaccinex), where indicated, post injection.
As negative controls, tumor-bearing mice were also treated with IgG4 and IgG2a. Control
antibodies were added to the treatment groups to match the total amount of protein delivered
in the combination group. Tumor volume was measured throughout the duration of the
experiment. After tumor growth had been recorded, animals were killed and tumors
removed for final determination of weight and sectioning and processing for
immunohistochemistry and immunofluorescence. All animal studies were approved by the
University of Maryland Office of Animal Welfare, Institutional Animal Care and Use
Committee, in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Immunofluorescence
Tumor tissues were processed for co-immunofluorescence as described [30]. Briefly, OCT-
embedded 8-μm-thick frozen tissue sections were cut onto silanated glass slides, air-dried,
and stored at −80 °C. Cryosections were thawed, hydrated, fixed, blocked in 10 % FBS, and
incubated overnight at 4 °C with primary antibodies diluted in a 2 % BSA/0.1 % Tween 20
solution in PBS. The following primary antibodies were used: anti-CD31 (anti-PECAM, BD
Pharmingen; 1:100 dilution); anti-PDGFRβ (Abcam, Cambridge, MA, 1:200 dilution). After
washing with PBS, the slides were incubated with FITC-conjugated anti-rat (Sigma) and
Texas red-conjugated anti-rabbit (Calbiochem, EMD Biosciences, San Diego, CA)
secondary antibodies for 1 h at room temperature. Finally, the slides were mounted with
Vectashield mounting medium with 4′,6-diamidino-2-phenylindole (Vector Laboratories,
Burlingame, CA). Slides were examined with a Nikon Eclipse E800 microscope system.
Blood vessel content was determined by counting the number of CD31-stained vessels in 10
fields at a magnification of 100× and calculating the average and standard deviation.
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Formalin-fixed, paraffin-embedded tumor tissues harvested from mice were processed for
immunohistochemistry as previously described [30]. Briefly, tissues were deparaffinized,
hydrated, rinsed with PBS, blocked in Power Block (BioGenex, Fremont CA), and
incubated overnight at 4 °C with primary antibodies diluted in a 2 % BSA/0.1 % Tween 20
solution in PBS. The following antibodies were used: Anti-Ki-67 (Santa Cruz Biotech, 1:50
dilution); anti-CD31 (anti-PECAM, BD Pharmingen; 1:100 dilution); anti-cleaved caspase 3
(Cell Signaling, Danvers, MA, 1:200 dilution). The slides were then washed in PBS,
incubated with biotinylated secondary antibody (Biotinylated Link Universal, DAKO North
America) for 45 min, and treated with strepavidin-HRP (DAKO North America) for 30 min
at room temperature. The slides were developed in 3,3-diaminobenzidine (FASTDAB
tablets; Sigma), counterstained with dilute Mayer’s hematoxylin, dehydrated, and mounted.
Images were taken with an Aperio ScanScope CS scanner (Aperio, Vista, CA).
Statistical analysis
Student’s paired t tests were performed on means, and p values calculated: *, p <0.05; **, p
<0.01.
Results
Semaphorin 4D increases in tumors in a background of VEGF inhibition
It is known that many different angiogenic factors are increased during cancer progression
and development, sometimes in response to anti-VEGF therapy, eventually leading to
treatment failure [5]. Our group and others have identified SEMA4D as a pro-angiogenic
protein, shed by some solid tumors, that acts through Plexin-B1 on endothelial cells to
enhance vessel growth into the developing malignancy [12–14]. Therefore, we looked for
changes in SEMA4D protein and message in tumors and cell lines undergoing different anti-
VEGF therapies to look for changes in the setting of VEGF blockade. Tumors comprised of
HN12 cells infected with control lentiviruses or lentiviruses coding for VEGF short hairpin
(sh) RNA, or grown in mice receiving anti-VEGF antibody injections, were harvested and
processed to detect protein levels of SEMA4D. We noted high basal levels of SEMA4D,
confirming our earlier findings [18, 31] but an increase in SEMA4D protein in tumors where
VEGF had been silenced by shRNA when compared to controls (Fig. 1a, left, upper panel).
Tumors harvested from anti-VEGF antibody-treated animals expressed higher levels of
SEMA4D protein compared with IgG-treated controls (Fig. 1a, right, upper panel). Both
tumors comprised of VEGF shRNA-infected HN12 cells and those harvested from mice
receiving anti-VEGF antibody therapy expressed higher levels of SEMA4D message
compared with their respective controls (Fig. 1b). To investigate these results in vitro and
determine whether there could be a direct, micro-environment-independent feedback
mechanism between VEGF and SEMA4D, we grew HN12, HN13, and HN30 cells in tissue
culture, infected them with lentiviruses coding for VEGF shRNA and looked for changes in
levels of SEMA4D protein. We confirmed VEGF knockdown in these cell lines (Fig. 1c, top
row). As before, SEMA4D protein levels were increased in VEGF shRNA-infected cells
versus control-infected cells (Fig. 1c, middle row). We again confirmed this effect at the
transcriptional level, as VEGF shRNA-infected HN12, 13, and 30 cells expressed higher
levels of SEMA4D message compared with controls (Fig. 1d). Taken together, these results
suggest that SEMA4D, a pro-angiogenic protein strongly expressed in HNSCC cells and
tumors, is further upregulated at the level of mRNA in HNSCC tumor tissues and cell lines
where VEGF function is inhibited.
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A comparison of the in vitro pro-angiogenic effects of SEMA4D/Plexin-B1 and VEGF/VEGF-
R2
Having established that SEMA4D increases in some anti-VEGF-treated tumors, we wanted
to determine the in vitro angiogenic capacity of SEMA4D in comparison with VEGF. We
employed HUVEC, control-infected or infected with Plexin-B1 shRNA-expressing
lentiviruses or VEGFR-2 shRNA-expressing lentiviruses. Infected cells exhibited reduced
expression of these proteins, respectively (Fig. 2a). When tested in a Boyden chamber
migration assay, sSE-MA4D acted as a strong promoter of cell migration compared with
controls, but not when its receptor, Plexin-B1, was knocked down with the appropriate
shRNA (Fig. 2b). VEGF induced a slightly stronger angiogenic response, which was
abrogated in cells infected with VEGR-2 shRNA-expressing lentiviruses (Fig. 2b). When
combined, sSEMA4D and VEGF promoted a more robust migratory response than either
chemoattractant alone and greater than that seen in positive control cells migrating toward
FBS. These results, which were statistically significant, are shown in the bar graph in Fig.
2c. We then looked for the ability of HUVEC growing on reconstituted basement membrane
material to form tube-like capillary structures in tissue culture under identical conditions,
which is indicative of a pro-angiogenic response. In both sSEMA4D and VEGF, HUVEC
formed a capillary network, although not when infected with Plexin-B1 or VEGFR-2
shRNA-expressing lentiviruses, respectively (Fig. 2d). When combined, VEGF and
sSEMA4D exhibited a greater response than either pro-angiogenic factor alone and greater
than that seen in the positive control (Fig. 2d). These results are quantified in the bar graph
in Fig. 2e. Taken together, these results indicate that SEMA4D alone can elicit a significant
pro-angiogenic response in HUVEC similar to that of VEGF and that together SEMA4D and
VEGF combine to yield a greater in vitro angiogenic phenotype compared with either factor
alone.
SEMA4D alone induces angiogenesis and cooperates with VEGF to elicit a stronger
response in vivo
To compare the angiogenic effects of SEMA4D and VEGF in vivo, we performed an
angiogenesis assay in immuno-compromised nude mice implanted with silicon tubes
(angioreactors) containing reconstituted basement membrane material mixed with PBS,
basic fibroblast growth factor (FGF), sSEMA4D or VEGF, and receiving injections of
isotype IgG control, anti-VEGF or anti-SEMA4D antibody, or both. FGF, which was used
as a positive control, induced blood vessels to grow into the open end of the reactor while
PBS failed to do so (Fig. 3a, left panel). Angioreactors containing either sSEMA4D or
VEGF exhibited vessel growth into the open end of the reactor tube significantly above that
for negative controls, with a slightly better response seen for VEGF (Fig. 3a, right panel). In
vivo angiogenesis could be blocked for both factors with treatment with the corresponding
blocking antibody. When present together, both sSEMA4D and VEGF elicited a more
robust in vivo angiogenic response than either alone, but one that could be reduced by
injections with both anti-VEGF-and anti-SEMA4D-blocking antibodies (Fig. 3a). These
results are quantified in Fig. 3b, based upon FITC-lectin fluorescence binding to the
endothelial cell contents of the angioreactors [27]. Taken together, these results show that
SEMA4D can elicit a significant pro-angiogenic response in vivo similar to that of VEGF,
even in the absence of VEGF, which would occur in the context of administration of anti-
VEGF blocking antibody therapy. While SEMA4D and VEGF combine to yield a greater in
vivo angiogenic response than either factor alone, the loss of angiogenesis observed when
both inhibiting antibodies are used in combined therapy further suggests a role for blockade
of both of these factors in the inhibition of pathological angiogenesis.
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Production of SEMA4D and VEGF by HNSCC contributes to an in vitro pro-angiogenic
phenotype in HUVEC
As in lymphocytes [32] and platelets [33], SEMA4D is shed into the environment by tumor
cells and acts on distant target tissues to exert its effects [13]. To specifically explore the
effects on angiogenesis of tumor-produced SEMA4D relative to VEGF in vitro, we used
HN12 cells, control-infected or infected with SEMA4D shRNA-expressing lentiviruses or
VEGF shRNA-expressing lentiviruses. Infected cells exhibited reduced levels of protein
compared with controls (Fig. 4a, top left and right panels). When the conditioned media
from these cells were used as chemoattractants for HUVEC in a Boyden chamber migration
assay, we observed that HUVEC migrated toward media from control-infected HN12 cells,
but less so toward media from HN12 infected with lentiviruses coding for SEMA4D shRNA
or VEGF shRNA (Fig. 4b). Media conditioned by HN12 cells infected with both SEMA4D
and VEGF shRNA lentiviruses induced the least amount of HUVEC migration, comparable
to that seen in negative controls (Fig. 4b). These results are quantified in the graph shown in
Fig. 4c. We then performed a tubulogenesis assay on HUVEC growing on reconstituted
basement membrane material in serum-free media conditioned by HN12 cells, control-
infected or infected with lentiviruses coding for VEGF shRNA or SEMA4D shRNA. When
cultured with 10 % FBS or in media conditioned by control-infected cells, HUVEC formed a
recognizable capillary network, but less so when cultured with media conditioned by HN12
infected with SEMA4D shRNA-expressing lentiviruses or VEGF shRNA-expressing
lentiviruses (Fig. 4d). Capillary formation was most inhibited when HUVEC were cultured
in media conditioned by HN12 where both SEMA4D and VEGF were silenced (Fig. 4d).
These results are quantified in the bar graph in Fig. 4e. Taken together, these results show
that tumor-derived SEMA4D and VEGF are important in promoting HUVEC migration and
capillary formation and that silencing both of these factors exerts a profound inhibition on in
vitro angiogenesis.
HNSCC-mediated production of SEMA4D and VEGF cooperate to promote neoplastic cell
proliferation, tumor growth and vascularity
Since anti-VEGF therapy increased SEMA4D production in HNSCC tumors and cell lines
and we observed SEMA4D to be strongly pro-angiogenic, similar to VEGF, we wanted to
examine whether SEMA4D blockade augmented inhibition of tumor growth and vascularity
seen in anti-VEGF therapy. We used the same populations of HN12 cells, control-infected
or infected with VEGF shRNA or SEMA4D shRNA-expressing lentiviruses, injected
subcutaneously into the flanks of immunocompromised nude mice. Tumor sizes were
measured until kill, when they were photographed, weighed, and processed for
immunohistochemistry and immunofluorescence. Tumors comprised of HN12 cells infected
with SEMA4D shRNA-expressing lentiviruses were smaller than controls, whereas in HN12
cells infected with VEGF shRNA-expressing lentiviruses were slightly smaller still (Fig.
5a). In tumors comprised of cells that failed to express both SEMA4D and VEGF, growth
was suppressed the greatest (Fig. 5a). Tumor volumes are shown graphically in Fig. 5b.
Tumor weights were taken and show a similar pattern, with tumors that failed to express
SEMA4D weighing about half that of controls and tumors that failed to express VEGF
weighing slightly less (Fig. 5c). Tumors comprised of cells infected with lentiviruses
expressing both SEMA4D and VEGF shRNA exhibited the greatest weight reduction (Fig.
5c). Knowing the influence of VEGF and SEMA4D on tumor-induced angiogenesis, we
processed the tumor tissues for CD31 expression in immunofluorescence to look for vessel
content. SEMA4D shRNA and VEGF shRNA-expressing lentiviruses both reduced blood
vessel content of tumors compared to controls, with inhibition of VEGF showing a slightly
greater response, buttogether exhibited a greater effect in decreasing tumor vascularity (Fig.
5d). These results are shown graphicallyin Fig. 5e. To determine the maturity of blood
vessels in these tumors, we performed co-immunofluorescence to look for pericyte coverage
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of endothelial cells. We observed fewer and more immature blood vessels, as evidenced by a
lack of pericyte coverage, in the stroma of tumors from HN12 cells infected with SEMA4D
shRNA-expressing lentivirus compared with controls (Fig. 5f). The number of vessels in
tumors comprisedof VEGFshRNA-infected cells wasalso reduced butthese vessels exhibited
a mature phenotype, with well-formed pericyte sheaths surrounding the endothelial cells
(Fig. 5f), as has been reported elsewhere [34], indicating a qualitative difference from
vessels in tumors where SEMA4D expression is silenced. Importantly, vessels from tumors
expressing both SEMA4D and VEGF shRNA exhibited an even greater reduction in vessel
count and also lacked close pericyte association (Fig. 5f).
We then processed these tumors to look at tumor cell growth, staining for Ki-67 expression,
and apoptosis, using anti-cleaved caspase 3 antibody. Both shRNAs reduced proliferation of
tumor cells, with SEMA4D shRNA exhibiting a slightly greater inhibition compared with
VEGF shRNA (Fig. 6a). Together these two shRNA-expressing lentiviruses inhibited tumor
cell proliferation greater than each one alone (Fig. 6a). These results are quantified in the bar
graph in Fig. 6b. We then looked for the presence of cleaved caspase 3 fragment in these
tumors, as an indicator of active apoptosis. At first, we observed very little cleaved caspase
3 in control-infected tumors and a much stronger signal in tumor tissues comprised of
SEMA4D shRNA and VEGF shRNA-infected cells, either alone or together. Upon further
examination we noted that the pattern of staining, instead of representing tumor cells,
appeared to more closely resemble the distribution of blood vessels. Therefore, we
performed immunohistochemistry on serial sections of these tumors for cleaved caspase 3
and CD31, looking for apoptosis that co-localized with endothelial cells. We observed very
little cleaved caspase 3 in control-infected tumors (Fig. 6c, left column, lower panel). In
tumors comprised of cells infected with SEMA4D shRNA or VEGF shRNA-expressing
lentivirus, we observed more cleaved caspase 3 compared with controls, which
corresponded with CD31 staining in the serial sections (Fig. 6c, second and third columns,
respectively). The highest expression of cleaved caspase 3 was observed in tumors where
the cells were infected with both types of lentiviruses (Fig. 6c, right column). These results
are quantified in the bar graph in Fig. 6d. Taken together, these results suggest that
SEMA4D and VEGF are produced by HNSCC for the purposes of enhancing vascularity, at
least partly through protection of endothelial cells against apoptosis, in order to support
tumor growth and survival, and that SEMA4D blockade enhances the anti-cancer activity of
anti-VEGF therapy.
Anti-SEMA4D therapy reduces tumor growth and vascularity of tumors resistant to anti-
VEGF treatment
Because interference with SEMA4D functioning, either through blocking antibodies or
shRNA knock down, could inhibit angiogenesis in vitro and in vivo and suppress the growth
and vascularity of malignancies similar to that seen in VEGF/VEGFR-2 inhibition, we
wanted to look at the ability of anti-SEMA4D therapy to rescue inhibition of tumor-induced
angiogenesis and restrict tumor growth in the setting of loss of response to anti-VEGF
therapy. Therefore, we injected CT26 tumor cells, which are resistant to anti-VEGF
treatment [5], subcutaneously into host mice and treated with IgG control or anti-VEGF
antibody. As expected, the tumors in anti-VEGF antibody-treated mice continued to grow at
a rate similar to that seen in IgG-treated controls (Fig. 7a), reflecting a clinical situation
where anti-VEGF treatment was unsuccessful and a different anti-angiogenic intervention
was needed. Therefore, in two anti-VEGF antibody groups, treatment was changed to either
IgG isotype control or anti-SEMA4D antibody starting on day 9. On day 18, the mice were
killed and the tumors were photographed, weighed, and processed for immunofluorescence.
We noted reduced sizes of tumors in mice switched to anti-SEMA4D antibody treatment
compared with IgG controls or mice which received anti-VEGF antibody injections
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throughout the experiment (Fig. 7a). Tumor volumes are shown graphically in Fig. 7b and
demonstrate that following the initial period of anti-VEGF therapy ‘failure,’ mice receiving
anti-SEMA4D antibody injections during the latter half of the experiment exhibited
significant reductions in tumor size compared with other groups (Fig. 7b). Tumor weights
show a similar pattern, with tumors from mice receiving anti-VEGF antibody for the full 18
days and those receiving anti-VEGF antibody followed by IgG exhibiting similar weights to
tumors from mice treated only with IgG (Fig. 7c). Tumor weights were reduced in mice
receiving anti-SEMA4D antibody injections for the last 9 days (Fig. 7c). We then processed
the tumors for CD31 expression in immunofluorescence to look for vessel content. Tumors
from mice receiving either IgG or VEGF alone or anti-VEGF followed by IgG were highly
vascular but there was a great reduction in vessel content in CT26 tumors harvested from
mice where treatment was changed to anti-SEMA4D antibody injections (Fig. 7d). These
results, which are shown graphically in Fig. 7e, suggest that anti-SEMA4D therapy could be
a viable adjunct in the treatment of anti-VEGF therapy-resistant tumors.
Discussion
The role of VEGF- and VEGFR-2 in tumor-induced angiogenesis has been well
characterized. As a result, these proteins have been targeted as part of a treatment strategy
for different neoplasms. Unfortunately, anti-VEGF therapies have failed to live up to
expectations or extend cancer patient survival for more than a few months [35, 36]. It is now
recognized that other angiogenic factors are upregulated during cancer progression and
development, sometimes as a direct response to anti-VEGF therapy, and that failure of anti-
angiogenic treatment can often be traced to the induction of these factors. Their
identification is important, as they could also be targeted concurrently with VEGF in order
to overcome anti-angiogenic evasion. Here, we show that anti-VEGF therapy increases
SEMA4D production in tumor tissues and in cell culture and provide evidence that
SEMA4D-mediated induction of angiogenesis plays a significant role in the growth and
vascularity of HNSCC and possibly other cancers. Indeed, while SEMA4D cooperates with
VEGF to promote angiogenesis and tumor progression, it also exerts significant effects
when acting alone, as might occur in the background of anti-VEGF therapy.
There is great interest in determining the mechanism of how interference with VEGF
upregulates other pro-angiogenic factors [37]. One possibility is that anti-VEGF therapy
causes severe in intratumoral hypoxia, which could stimulate HIF-1-mediated production of
other angiogenic factors by tumor cells. Fischer, et al. [5] have shown that VEGF blockade
increases hypoxia and subsequently transcription of the pro-angiogenic genes Sdf-1, Fgf-1,
Fgf-2, and Plgf. There is evidence in the literature that plexins and semaphorins are also
regulated by changes in oxygen tension [38–40], while we recently have shown dramatic
upregulation of SEMA4D protein and mRNA occurring in a HIF-dependent manner [31].
The results presented here demonstrate that increases in SEMA4D occur at the
transcriptional level, so hypoxia and its associated transcription factors may in fact play a
role. However, not all pro-angiogenic factors are influenced by hypoxia and not all anti-
angiogenic interventions result in intratumoral hypoxia and increased levels of active HIF-1,
casting doubt on a ‘global’ mechanism for hypoxic regulation for pro-angiogenic genes,
including that of semaphorins. An alternative mechanism of angiogenic control might be
contributions of pro-angiogenic and pro-inflammatory mediators from tumor associated
macrophages (TAMs) and cancer-associated fibroblasts (CAFs) [41, 42]. TAMs account for
the majority of the infiltrating inflammatory cells in a tumor mass and play an important role
during tumor progression [43], producing factors that promote angiogenesis not only in
mouse tumor xenograft models [44] but also in human cancers [45]. CT26 tumors likely are
resistant to anti-VEGF treatment because they induce macrophage infiltration [5]. Since
TAMs have been shown to produce SEMA4D, which contributes significantly to tumor-
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induced angiogenesis [41], perhaps this is another way anti-SEMA4D treatment successfully
opposes induction of angiogenesis and could explain why SEMA4D blocking antibodies
were so effective in reducing the growth and vascularity of CT26 tumors in our experiments.
We observed elevated SEMA4D expression in response to loss of VEGF not only in a
mouse model but also in vitro, suggesting a host or microenvironment-independent feedback
mechanism where cancer cells directly respond to changes in VEGF levels. While we have
not detected VEGFR expression in most HNSCC cell lines examined (data not shown),
cancer cells do in fact express another VEGF receptor, neuropilin-1 (NP-1), which has
become a valid anti-tumor target in a variety of malignancies [46]. NPs mostly function as
co-receptors that interact with other cell surface proteins to generate a signal. For example,
VEGF engagement of NP-1 activates Met [47], a cell surface receptor homologous to the
semaphorins and plexins that engages numerous downstream pathways, including NF-κB. In
turn, NF-κB has been shown to inhibit HIF-1 activity [48], both in its ability to block HIF-1
transactivation of hypoxia responsive genes [49] and at the level of expression of the
HIF-1α protein subunit [50]. Interestingly, there is evidence of direct NF-κB control over
the HIF-1β promoter as well [51], a finding consistent with our data demonstrating elevated
HIF-1β protein levels in HNSCC cells with silenced VEGF (unpublished observations).
Therefore, we propose a possible mechanism where loss of VEGF signaling through NP-1
results in alleviation of NF-κB-mediated repression of HIF (either at the level of HIF
activity or HIF-1α and β protein levels), and subsequent activation of SEMA4D
transcription. Indeed, we have determined that Plexin-B1 itself activates NF-κB in a process
necessary for angiogenesis [52], a pathway that could also serve as a negative feedback loop
to turn off SEMA4D signaling in normal cells and tissues where appropriate. However, there
are likely numerous feedback mechanisms between VEGF, SEMA4D and other pro-
angiogenic factors that remain unexplored.
We have previously demonstrated that SEMA4D is expressed by many different cell lines
and aggressive carcinomas [18] and that it is shed by tumor cells into the surrounding
environment in a manner analogous to VEGF to act on endothelial cells and promote
angiogenesis [13]. Here, when we compared the pro-angiogenic effects of SEMA4D with
VEGF directly, we showed that SEMA4D potently induced angiogenesis to levels similar to
that seem for VEGF. However, there appears to be some differences in the effects on tumor
growth and vascularity between these two proteins. Interfering with SEMA4D and Plexin-
B1 inhibited HUVEC migration and tube formation in vitro, as well as inhibiting in vivo
angiogenesis, to levels comparable to that seen in anti-VEGF therapy, while VEGF blockade
was slightly more effective in reducing tumor weight and volume. This is likely due to
differences in signaling between their respective receptors, with VEGFR-2 in general
inducing a more potent pro-angiogenic effect than Plexin-B1. However, it also possible that
SEMA4D and Plexin-B1 might have effects on tumor growth directly, mediated by co-
activation of the tyrosine kinase receptor Met [53], as previously noted. While we have not
thoroughly studied the proliferative effects of SEMA4D on tumor cells themselves, we did
note a greater decrease in Ki-67 staining from tumors where SEMA4D was silenced,
compared with those comprised of cells infected with VEGF shRNA-expressing virus.
There is evidence in the literature showing that tumors expressing high levels of SEMA4D
are more aggressive, more difficult to treat, and have a poor prognosis, without specifically
describing any effect on angiogenesis [54, 55]. A recent study of Semaphorin 3E
(SEMA3E)/Plexin-D1 signaling suggests that these proteins are able to act in an autocrine or
paracrine manner on tumor cells to enhance invasiveness but do so without affecting tumor
size or vascularity, as SEMA3E is actually anti-angiogenic [56].
Further differences between the effects of VEGF and SEMA4D on tumors were reflected in
differences in vessel maturity. Vessels from tumors composed of cells infected with VEGF
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shRNA-expressing lentivirus demonstrated a close association with pericytes, similar to
what others have reported [34], while tumors composed of cells infected with SEMA4D
shRNA-expressing lentiviruses, or of cells infected with both lentiviruses, lacked this
organization. We are not sure of the significance of these findings, except that vessels not
associated with pericyte sheaths are more immature, leaky, less capable of remodeling, and
may be more reliant on growth factors for survival. If blocking SEMA4D function inhibits
vascular maturation and remodeling, it could render vessels more reliant on VEGF for
survival and thus more susceptible to anti-VEGF antibody or VEGF-trap approaches in
some sort of combined therapy. In fact, we did observe enhanced endothelial cell apoptosis
in tumors where both SEMA4D and VEGF were silenced, which resulted in greatly reduced
tumor size. Finally, anti-SEMA4D antibody partially rescued growth inhibition in anti-
VEGF therapy-resistant CT26 tumors, which was reflected in decreased blood vessel
content, suggesting that SEMA4D blockade could be an excellent form of treatment for
some malignancies concurrent with anti-VEGF therapy or when anti-VEGF therapy has
failed. Anti-SEMA4D therapy also would likely be very safe, as Plexin-B1 signaling is
redundant in normal vascular development [57] but as we have shown contributes
significantly to angiogenesis in malignancies.
In conclusion, we show that the ability of tumors to overcome or evade anti-angiogenic
therapies is at least in part determined by the pro-angiogenic protein SEMA4D. In this
study, we show that SEMA4D contributes to tumor-induced angiogenesis and that SEMA4D
blockade enhances the anti-cancer activity of anti-VEGF treatments. Interference with
SEMA4D-mediated pathways could be a viable adjunct to anti-VEGF therapy.
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SEMA4D expression is elevated in HNSCC tumors and cell lines where VEGF function is
inhibited by VEGF shRNA or anti-VEGF antibody. a Immunoblots for SEMA4D (upper
panels) from tissue extracts of HN12 tumors comprised of control-infected cells (C) or cells
infected with lentiviruses-expressing VEGF shRNA (VEGF shRNA, left panels) or from
tumors where mice were treated with control antibody (IgG) or anti-VEGF antibody (anti-
VEGF Ab) injections (right panels). b RNA was extracted from tumors from (a) to detect
steady-state SEMA4D transcripts in a quantitative PCR analysis. The bar graph represents
the ratio of SEMA4D mRNA to 18S mRNA, relative to controls, from three independent
experiments (*p <0.05). c Immunoblot for VEGF (upper panel) and SEMA4D (middle
panel) from HN12, 13 and 30 cells growing in culture, infected with control lentivirus (C) or
lentivirus-expressing VEGF shRNA (VEGF shRNA). For all immunoblots, GAPDH was
used as the loading control (lower panels). d RNA was extracted to detect steady-state
SEMA4D transcripts in a quantitative PCR analysis from HN12, 13, and 30 cells from (c).
The bar graphs represent the ratio of SEMA4D mRNA to 18S mRNA, relative to controls,
from three independent experiments (*p <0.05)
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SEMA4D and VEGF act together to promote endothelial cell migration and tube formation
in vitro. a Immunoblot analysis for the SEMA4D receptor Plexin-B1 (left, upper panel) and
the VEGF receptor VEGFR-2 (right, upper panel) in lysates from HUVEC infected with
empty vector control lentivirus (C) or virus coding for the appropriate shRNA. GAPDH was
used as a loading control (lower panels). b Control or shRNA-expressing lentivirus-infected
HUVEC from (a) were examined in a Boyden chamber for migration toward 0.1 % BSA
(negative control), 10 % FBS (positive control), SEMA4D, VEGF, or both. c The results of
the migration assay, expressed as pixel intensity of scanned stained migration membranes
relative to negative controls. Error bars represent the standard deviation from three
independent experiments (*p <0.05). d Control or shRNA-expressing lentivirus-infected
HUVEC from (a) were plated on reconstituted basement membrane material in serum-free
media with 0.1 % BSA (negative control), 10 % FBS (positive control), SEMA4D, VEGF or
both and examined for formation of capillary tubes. e Quantification of the results of the
tubulogenesis assay, measuring, and summing the length of all tubular structures observed in
10 random fields. Error bars represent the standard deviation from three independent
experiments (*p <0.05)
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SEMA4D is a potent pro-angiogenic compound that cooperates with VEGF to enhance
angiogenesis in vivo. a A DIVAA assay was performed in mice receiving injections of the
indicated antibodies, measuring blood vessel growth into angioreactors containing
reconstituted basement membrane material alone, or material mixed with VEGF, SEMA4D,
or both. Negative and positive controls contain PBS and FGF, respectively (left panel).
Photographs of representative angioreactors from the experiment are shown (right panels). b
Quantification of blood vessel growth, as measured by FITC-lectin fluorescence (in arbitrary
units, AU) from endothelial cell contents of each reactor, relative to negative controls (Y-
axis). Error bars represent the standard deviation from four reactors (*p <0.05; **p <0.01)
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SEMA4D and VEGF are produced by HNSCC and promote endothelial cell migration and
tube formation in vitro. a Immunoblot analysis for SEMA4D (upper panel, left) and VEGF
(upper right) in lysates from HN12 cells infected with empty vector control lentivirus (C) or
virus coding for SEMA4D shRNA or VEGF shRNA, where indicated. GAPDH was used as
a loading control (lower panels). b Boyden chamber migration assay in HUVEC toward 0.1
% BSA (negative control), 10 % FBS (positive control) or serum-free media conditioned by
HN12 cells, control-infected or infected with lenti-virus coding for SEMA4D shRNA,
VEGF shRNA, or both. c Results of the migration assay from (b), quantified as the pixel
intensity of scanned migration assay membranes relative to the negative control. Error bars
represent the standard deviation from the averages from three wells (*p <0.05; **p <0.01). d
HUVEC were plated on reconstituted basement membrane material in media containing 0.1
% BSA (negative control), 10 % FBS (positive control) or serum-free media conditioned by
HN12 cells, control-infected or infected with lentivirus coding for SEMA4D shRNA, VEGF
shRNA, or both, and examined for formation of capillary tubes. Representative photographs
are shown. e Quantification of the results of the tubulogenesis assay, measuring, and
Zhou et al. Page 19













summing the length of all tubular structures observed in 10 random fields. Error bars
represent the standard deviation from three independent experiments (*p <0.05; **p <0.01)
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Production of SEMA4D by HNSCC cooperates with VEGF to promote tumor-induced
angiogenesis. a HN12 cells infected with lentiviruses coding for control shRNA, SEMA4D
shRNA, VEGF shRNA, or both were injected subcutaneously into nude mice along with a
bolus of basement membrane extract. Representative tumors are shown at the time of kill. b
The results of tumor volume measurement in cm3 are shown (n = 10; *p <0.05). c The
results of tumor weights in mg are shown (n = 10; *, p <0.05; **p <0.01). d
Immunofluorescence for CD31 as a measure of vascular density from tumors derived from
HN12 cells infected with a control lentivirus (control shRNA), lentivirus-expressing
SEMA4D shRNA or VEGF shRNA, or both. Nuclei are stained with DAPI. e Results of
measurement of vascular content from these tumors, determined by the average number of
vessels in 10 high-power fields (hpf) of CD31-stained sections, are quantified in the bar
graph (*p <0.05; **p <0.01). f Immunofluorescence for vessels (green, top row) and
pericytes (red, middle row) in the same tumor populations, looking for association of
pericytes with endothelial cells (merge, bottom row) as an indicator of vessel integrity and
maturity. Tumors from cells-expressing SEMA4D shRNA exhibit reduced numbers of
vessels that fail to associate with pericytes. Tumors comprised of HN12 cells infected with
VEGF shRNA-expressing lentivirus also fail to induce robust blood vessel growth, but those
vessels are closely associated with a pericyte sheath
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Production of SEMA4D and VEGF by HNSCC contributes to tumor cell proliferation and
endothelial cell survival in tumor vasculature. a Immunohistochemistry for Ki-67, to
measure proliferation of cells from tumors comprised of HN12 cells infected with control
lentivirus (control shRNA), lentivirus-expressing SEMA4D shRNA, VEGF shRNA, or both.
b Results of Ki-67 staining, expressed as percentage of positive cells observed from 10 high
power fields. Error bars represent the standard deviation of the averages from three
independent experiments (*p <0.05; **p <0.01). c The presence of cleaved caspase 3
(bottom row) was evaluated in tumors comprised of HN12 cells-expressing control shRNA,
SEMA4D shRNA, VEGF shRNA or both, correlated with tumor sections stained for
endothelial cells (CD31, top row). d Results of vascular apoptosis, expressed as percentage
of vessels exhibiting cleaved caspase 3 observed from 10 high power fields, is shown in the
bar graph (lower panel; p <0.05; **p <0.01)
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Anti-SEMA4D therapy reduces growth and vascularity of tumors resistant to anti-VEGF
treatment. a CT26 cells were injected subcutaneously into nude mice along with a bolus of
basement membrane extract. Control mice were treated with IgG isotype control (IgG) or
anti-VEGF antibody (anti-VEGF) for 18 days. Treatment for some mice receiving anti-
VEGF antibody was changed to IgG (anti-VEGF + IgG) or anti-SEMA4D antibody (anti-
VEGF + anti-SEM A4D) starting at day 9, extending until the end of the experiment (day
18). Representative tumors are shown at the time of kill. b The results of tumor volume
measurement in cm3 are shown (n = 10; *p <0.05; **p <0.01). c The results of tumor
weights in mg in mice treated with IgG or anti-VEGF antibody for the duration of the
experiment or in mice treated with anti-VEGF antibody from days 1 to 9 and then switched
to IgG or anti-SEMA4D antibody injections for days 9–18 (n = 10; *p <0.05). d
Immunofluorescence for CD31 as a measure of vascular density from tumors derived from
CT26 cells. e Results of measurement of vascular content from these tumors determined by
the average number of vessels in 10 high-power fields (hpf) for CD31-stained sections (*p
<0.05)
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